SCHEMBL30469984

SCHEMBL30469984

C[C@H]1CCC(c2ccc3sc(C(C)(C)N(C)C)nc3c2)=NC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29081431 1.00 — —
SCHEMBL29347517 1.00 — —
SCHEMBL29335687 0.86 PDE3B (0.34) —
SCHEMBL29082045 0.84 — —
SCHEMBL24367507 0.83 — —
SCHEMBL30470972 0.83 — —
SCHEMBL32688952 0.83 — —
SCHEMBL25321474 0.81 — —
SCHEMBL25322588 0.81 — —
SCHEMBL30514972 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 — — US disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 — — EP disclosed
Send feedback